中国P站

Translational Medicine; Cancer Therapy; Regenerative Medicine; Stem Cells; CRISPR/Cas9; Organoids; Neurological Disorders; Inflammatory Diseases; Exosome Drug Delivery; Single-cell Multi-omics

Introduction

This review explores the critical role of mRNA translation in cancer progression and resistance, highlighting how dysregulation of this fundamental cellular process drives tumorigenesis. It discusses various therapeutic strategies targeting translation initiation and elongation factors, ribosomal components, and non-coding RNAs, offering a translational perspective on developing new anti-cancer drugs by exploiting these vulnerabilities [1].

This article examines the immense potential of human pluripotent stem cells (hPSCs) in regenerative medicine, discussing their ability to differentiate into various cell types for tissue repair and disease modeling. It covers the advances in deriving and manipulating hPSCs, addresses the challenges of scalability and immunogenicity, and highlights current translational efforts to bring hPSC-based therapies to clinical application [2].

This paper reviews significant progress in understanding the cellular and molecular underpinnings of various neurological disorders, bridging basic science with potential therapeutic strategies. It discusses the application of advanced cell models, gene editing technologies, and omics approaches to identify novel targets and develop innovative treatments for conditions like Alzheimer's and Parkinson's disease, emphasizing the journey from bench to bedside [3].

This review highlights pyroptosis, a form of programmed necrotic cell death, as a critical mediator in the pathogenesis of various inflammatory diseases. It elucidates the molecular mechanisms underpinning pyroptosis activation and its contribution to disease progression, exploring the promising therapeutic potential of targeting key pyroptotic pathways to mitigate inflammation and treat related disorders [4].

This article highlights the transformative potential of human stem cell-derived organoids as sophisticated in vitro models for studying human diseases and accelerating drug discovery. It details how organoids faithfully recapitulate tissue-specific architectures and functions, allowing for personalized disease modeling, phenotype screening, and toxicology assessment, thereby paving the way for precision medicine approaches [5].

This article explores the groundbreaking impact of CRISPR/Cas9 gene editing technology on induced pluripotent stem cells (iPSCs), revolutionizing their application in regenerative medicine. It details how precise genetic modifications in iPSCs enable the correction of disease-causing mutations, generation of disease models, and development of novel cell-based therapies, while also addressing the challenges of off-target effects and delivery efficiency in a translational context [6].

This article delves into the intricate interplay of mitochondrial dynamics and bioenergetics, identifying them as crucial therapeutic targets for metabolic diseases. It highlights how dysregulation in mitochondrial fission, fusion, biogenesis, and turnover contributes to pathologies like diabetes and obesity, offering a translational outlook on developing interventions that restore mitochondrial function for improved metabolic health [7].

This review focuses on the burgeoning field of exosome-based drug delivery systems, particularly for cancer therapy. It discusses the intrinsic properties of exosomes that make them ideal natural nanoparticles for delivering therapeutic agents, highlighting their biocompatibility, low immunogenicity, and ability to cross biological barriers, while also addressing challenges in large-scale production and targeting specificity for clinical translation [8].

This article emphasizes the critical role of the stem cell microenvironment, or niche, in modulating stem cell fate and function for tissue regeneration. It explores innovative strategies in tissue engineering to precisely manipulate biophysical and biochemical cues within the niche, aiming to optimize stem cell behavior, enhance regenerative outcomes, and facilitate the translation of cell-based therapies for various damaged tissues and organs [9].

This article explores the revolutionary impact of single-cell multi-omics technologies on translational medicine, enabling unprecedented insights into cellular heterogeneity and complex biological processes. It discusses how these techniques, by simultaneously profiling genomics, transcriptomics, proteomics, and epigenomics at single-cell resolution, are uncovering novel disease mechanisms, identifying biomarkers, and guiding personalized therapeutic strategies across various diseases [10].

Description

Translational medicine consistently advances our understanding of disease mechanisms. The dysregulation of mRNA translation is critical in cancer progression and resistance, leading to exploration of therapeutic strategies targeting translation factors, ribosomal components, and non-coding RNAs for anti-cancer drug development [1]. Simultaneously, exosome-based drug delivery systems are showing promise for cancer therapy, using exosomes as natural nanoparticles with biocompatibility and barrier-crossing abilities, despite production and targeting challenges [8].

Human pluripotent stem cells (hPSCs) represent a significant potential in regenerative medicine, capable of differentiating into various cell types for tissue repair and disease modeling. Advances in their manipulation are accelerating hPSC-based therapies into clinical application, addressing challenges like scalability and immunogenicity [2]. CRISPR/Cas9 gene editing has revolutionized induced pluripotent stem cells (iPSCs), enabling precise genetic modifications for correcting disease mutations, generating models, and developing novel cell-based therapies, while still grappling with off-target effects and delivery efficiency [6].

The stem cell microenvironment, or niche, plays a vital role in modulating stem cell fate for tissue regeneration. Tissue engineering strategies manipulate biophysical and biochemical cues within this niche to optimize stem cell behavior, enhancing regenerative outcomes and facilitating translation of cell-based therapies [9]. Furthermore, human stem cell-derived organoids are becoming sophisticated in vitro models for disease study and drug discovery. These organoids recapitulate tissue architectures and functions, allowing for personalized disease modeling, phenotype screening, and toxicology assessment, thus advancing precision medicine [5].

Progress in neurological disorders bridges basic science with therapeutic strategies, applying advanced cell models, gene editing, and omics approaches to identify targets and develop treatments for conditions such as Alzheimer's and Parkinson's [3]. Concurrently, pyroptosis, a form of programmed necrotic cell death, is identified as a critical mediator in inflammatory diseases. Understanding its molecular mechanisms and contribution to disease progression offers promising therapeutic potential through targeting pyroptotic pathways to mitigate inflammation [4].

Mitochondrial dynamics and bioenergetics are crucial therapeutic targets for metabolic diseases. Dysregulation in mitochondrial fission, fusion, biogenesis, and turnover contributes to pathologies like diabetes and obesity, driving translational efforts to restore mitochondrial function for improved metabolic health [7]. Finally, single-cell multi-omics technologies are revolutionizing translational medicine. By simultaneously profiling genomics, transcriptomics, proteomics, and epigenomics at single-cell resolution, these techniques provide unprecedented insights into cellular heterogeneity, uncovering novel disease mechanisms, identifying biomarkers, and guiding personalized therapeutic strategies across various diseases [10].

Conclusion

Recent scientific advancements underscore key developments across translational medicine. Research highlights the critical role of mRNA translation in cancer, proposing therapeutic strategies that target its various components to combat tumorigenesis. Human pluripotent stem cells (hPSCs) show immense potential in regenerative medicine, with ongoing efforts to overcome scalability and immunogenicity challenges for clinical application. Significant strides are also being made in understanding neurological disorders, bridging basic science with new therapeutic strategies through advanced cell models, gene editing, and omics approaches for conditions like Alzheimer's and Parkinson's. Pyroptosis, a form of programmed cell death, is identified as a crucial mediator in inflammatory diseases, offering promising therapeutic targets. Furthermore, human stem cell-derived organoids are proving invaluable as in vitro models for disease study and drug discovery, facilitating personalized medicine. CRISPR/Cas9 gene editing of induced pluripotent stem cells (iPSCs) is revolutionizing regenerative medicine by enabling precise genetic modifications for disease correction and novel cell therapies. Mitochondrial dynamics and bioenergetics are recognized as vital therapeutic targets for metabolic diseases, with a focus on restoring mitochondrial function. The development of exosome-based drug delivery systems for cancer therapy leverages their natural properties, though challenges in production and targeting persist. Lastly, the stem cell microenvironment is critical for tissue regeneration, with engineered strategies optimizing stem cell behavior, and single-cell multi-omics technologies are providing unprecedented insights into cellular heterogeneity, guiding personalized therapeutic strategies.

References

1. Rona S, Tamar A, Noam Z (2023) .Nat Rev Cancer 23:781-802.

   , ,

2. Mohammad MA, Mohammed BJ, Reem RA (2024) .Stem Cells Dev 33:1-21.

   , ,

3. Shweta S, Shraddha S, Aashish S (2022) .Cell Mol Neurobiol 42:2157-2178.

   , ,

4. Zijian S, Hairong Z, Jianming C (2023) .Inflammopharmacology 31:1783-1798.

   , ,

5. Ying X, Bo H, Shuzhen L (2021) .Genes Dis 8:690-705.

   , ,

6. Ching C, Meng-An TH, Yi-Han F (2021) .Int J Mol Sci 22:4070.

   , ,

7. Ranjan S, Sneha DB, Amit KS (2023) .Transl Res 259:86-101.

   , ,

8. Hao C, Jie Y, Shan W (2023) .J Nanobiotechnology 21:236.

   , ,

9. Yan Z, Qi M, Meng L (2020) .Adv Healthc Mater 9:2000570.

   , ,

10. Qi L, Bo WZ, Ya FS (2023) .J Transl Med 21:352.

    , ,